asoprisnil profile

asoprisnil: structure in first source [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]

ID Source	ID
PubMed CID	9577221
CHEMBL ID	267431
SCHEMBL ID	58611
MeSH ID	M0470817

Synonym
(8s,11r,13s,14s,17s)-11-[4-[(e)-hydroxyiminomethyl]phenyl]-17-methoxy-17-(methoxymethyl)-13-methyl-1,2,6,7,8,11,12,14,15,16-decahydrocyclopenta[a]phenanthren-3-one
j-867
asoprisnil
D02996
asoprisnil (usan/inn)
199396-76-4
4-[(11beta,17beta)-17-methoxy-17-(methoxymethyl)-3-oxoestra-4,9-dien-11-yl]benzaldehyde oxime
CHEMBL267431
j867
bay86-5294
j867 cpd
unii-72w09924wp
asoprisnil [usan:inn:ban]
72w09924wp ,
benzaldehyde, 4-((11beta,17beta)-17-methoxy-17-(methoxymethyl)-3-oxoestra-4,9-dien-11-yl)-, 1-oxime, (c(e))-
11beta-(4-((e)-(hydroxyimino)methyl)phenyl)-17beta-methoxy-17-(methoxymethyl)estra-4,9-dien-3-one
asoprisnil [mi]
benzaldehyde, 4-((11.beta.,17.beta.)-17-methoxy-17-(methoxymethyl)-3-oxoestra-4,9-dien-11-yl)-, 1-oxime, (c(e))-
benzaldehyde, 4-((11.beta.,17.beta.)-17-methoxy-17-(methoxymethyl)-3-oxoestra-4,9-dien-11-yl), 1-oxime, (c(e))
11beta-[4-[(e)-(hydroxyimino)methyl]phenyl]-17beta-methoxy-17-(methoxymethyl)estra-4,9-dien-3-one
asoprisnil [mart.]
asoprisnil [inn]
asoprisnil [who-dd]
asoprisnil [usan]
SCHEMBL58611
4-((8s,11r,13s,14s,17s)-17-methoxy-17-(methoxymethyl)-13-methyl-3-oxo-2,3,6,7,8,11,12,13,14,15,16,17-dodecahydro-1h-cyclopenta[a]phenanthren-11-yl)benzaldehyde oxime
4-[(11alpha,13alpha,17beta)-17-methoxy-17-(methoxymethyl)-3-oxoestra-4,9-dien-11-yl]benzaldehyde oxime
AKOS032946286
DTXSID40904033
HY-119433
DB06680
benzaldehyde, 4-[(11beta,17beta)-17-methoxy-17-(methoxymethyl)-3-oxoestra-4,9-dien-11-yl]-, 1-oxime, [c(e)]-
CS-0068353
MS-28149
ZHA39676

Excerpt	Reference	Relevance
"Asoprisnil is a novel selective steroid receptor modulator that shows unique pharmacodynamic effects in animal models and humans. "	( Asoprisnil (J867): a selective progesterone receptor modulator for gynecological therapy. Chwalisz, K; DeManno, D; Elger, W; Garg, R; Hess-Stumpp, H; Lee, R; Schneider, B; Schubert, G, 2003)	3.2
"Asoprisnil is a novel selective progesterone receptor modulator that exhibits partial agonist and antagonist activities in animals and humans. "	( Therapeutic potential for the selective progesterone receptor modulator asoprisnil in the treatment of leiomyomata. Chwalisz, K; DeManno, D; Garg, R; Larsen, L; Mattia-Goldberg, C; Stickler, T, 2004)	2
"Asoprisnil (J867) is a novel selective progesterone receptor modulator (SPRM) that exhibits partial agonist and antagonist activities and tissue selective effects. "	( The effects of 1-month administration of asoprisnil (J867), a selective progesterone receptor modulator, in healthy premenopausal women. Chwalisz, K; Elger, W; Larsen, L; Mattia-Goldberg, C; Stickler, T, 2005)	2.04
"Asoprisnil is a selective progesterone receptor modulator with mixed progesterone agonist/antagonist activity which controls uterine bleeding via an endometrial effect. "	( The effects of the selective progesterone receptor modulator asoprisnil on the morphology of uterine tissues after 3 months treatment in patients with symptomatic uterine leiomyomata. Cameron, IT; Chwalisz, K; Critchley, HO; Han, C; Ingamells, S; Osei, J; Williams, AR, 2007)	2.02

Excerpt	Reference	Relevance
"In asoprisnil-treated endometrium, there is a marked downregulation of stromal PR expression and virtual absence of uNK."	( Uterine NK cells regulate endometrial bleeding in women and are suppressed by the progesterone receptor modulator asoprisnil. Brito-Mutunayagam, SL; Cameron, IT; Chwalisz, K; Craigon, M; Critchley, HO; Forster, T; Ghazal, P; Gibson, DA; Lourenco, P; Male, V; Moffett, A; Wilkens, J; Williams, AR, 2013)	1.11
"Each asoprisnil treatment was compared with placebo."	( Effects of the selective progesterone receptor modulator asoprisnil on uterine artery blood flow, ovarian activity, and clinical symptoms in patients with uterine leiomyomata scheduled for hysterectomy. Cameron, IT; Chwalisz, K; Critchley, HO; Han, C; Hapangama, D; Ingamells, S; Lawrence, AC; Lumsden, MA; Walker, J; Wilkens, J; Williams, AR, 2008)	1.05
"Asoprisnil treatment was well tolerated when administered daily for a 12-wk period, and no serious adverse events occurred."	( Effects of the selective progesterone receptor modulator asoprisnil on uterine artery blood flow, ovarian activity, and clinical symptoms in patients with uterine leiomyomata scheduled for hysterectomy. Cameron, IT; Chwalisz, K; Critchley, HO; Han, C; Hapangama, D; Ingamells, S; Lawrence, AC; Lumsden, MA; Walker, J; Wilkens, J; Williams, AR, 2008)	1.31
"Asoprisnil treatment significantly (P < 0.05) increased TRAIL, DR4, and DR5 contents in cultured leiomyoma cells in a dose-dependent manner with a cleavage of caspase-8, -7, and -3, and decreased X-linked chromosome-linked inhibitor of apoptosis protein contents."	( A novel selective progesterone receptor modulator asoprisnil activates tumor necrosis factor-related apoptosis-inducing ligand (TRAIL)-mediated signaling pathway in cultured human uterine leiomyoma cells in the absence of comparable effects on myometrial Chwalisz, K; DeManno, DA; Maruo, T; Ohara, N; Sasaki, H; Wang, J; Xu, Q; Yoshida, S, 2007)	1.31
"Treatment with asoprisnil decreased the proliferating cell nuclear antigen-positive rate and the number of viable cells and increased the terminal deoxynucleotidyl transferase-mediated 2'-deoxyuridine 5'-triphosphate nick end labeling- positive rate in cultured leiomyoma cells in a dose-dependent manner ( P < .05)."	( Comparative effects of SPRM asoprisnil (J867) on proliferation, apoptosis, and the expression of growth factors in cultured uterine leiomyoma cells and normal myometrial cells. Chen, W; Chwalisz, K; DeManno, DA; Maruo, T; Morikawa, A; Ohara, N; Wang, J, 2007)	0.97
"Treatment with asoprisnil at concentrations > or =10(-7) M for 48 h significantly (P < 0.05) increased EMMPRIN, MMP-1 and MT1-MMP protein contents, and decreased TIMP-1 (P < 0.05), TIMP-2 (P < 0.01), type I (P < 0.01) and type III (P < 0.05 at 10(-7) M; P < 0.01 at 10(-6) M) collagen protein contents in cultured leiomyoma cells compared with control cultures."	( Selective progesterone receptor modulator asoprisnil down-regulates collagen synthesis in cultured human uterine leiomyoma cells through up-regulating extracellular matrix metalloproteinase inducer. Chwalisz, K; DeManno, DA; Maruo, T; Morikawa, A; Nakabayashi, K; Ohara, N; Xu, Q; Yoshida, S, 2008)	0.95

Excerpt	Reference	Relevance
"Uninterrupted treatment with asoprisnil for 12 months effectively controlled HMB and reduced fibroid and uterine volume with few adverse events."	( Safety and efficacy of the selective progesterone receptor modulator asoprisnil for heavy menstrual bleeding with uterine fibroids: pooled analysis of two 12-month, placebo-controlled, randomized trials. Carr, BR; Chwalisz, K; Diamond, MP; Elger, W; Feldman, RA; Mattia-Goldberg, C; Myers, ER; Schwefel, BM; Stewart, EA; Williams, ARW, 2019)	1.04

Excerpt	Relevance	Reference
" In low dosage and high dosage asoprisnil groups, the tight junction was longer and more curve than in the vehicle control group; microvilli were uneven and asymmetrically distributed in luminal epithelia; the stromal cells were small and the decidual change was not significant; there were karyopyknosis and karyolysis in stromal cells; there were abnormal thick-wall vessels in the endometrium."	( Postcoital administration of asoprisnil inhibited embryo implantation and disturbed ultrastructure of endometrium in implantation window in mice. Qiu, J; Shen, XL; Su, P; Wu, XL; Yang, YH; Yu, ZH, 2013)	0.97

Protein	Taxonomy	Measurement	Average	Min (ref.)	Avg (ref.)	Max (ref.)	Bioassay(s)
Estrogen receptor	Homo sapiens (human)	IC50 (µMol)	1.9500	0.0000	0.7237	32.7000	AID326408; AID719371
Glucocorticoid receptor	Homo sapiens (human)	IC50 (µMol)	0.1025	0.0000	0.4953	10.0000	AID326404; AID719373
Progesterone receptor	Homo sapiens (human)	IC50 (µMol)	0.0003	0.0000	0.5807	10.0000	AID323989; AID719375; AID719529
Mineralocorticoid receptor	Homo sapiens (human)	IC50 (µMol)	1.6000	0.0003	0.7484	10.0000	AID326406; AID719372
Androgen receptor	Homo sapiens (human)	IC50 (µMol)	0.0075	0.0000	0.8753	10.0000	AID326402; AID719374
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Protein	Taxonomy	Measurement	Average	Min (ref.)	Avg (ref.)	Max (ref.)	Bioassay(s)
Progesterone receptor	Homo sapiens (human)	EC50 (µMol)	0.1000	0.0001	0.4047	8.2000	AID323987
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Process	via Protein(s)	Taxonomy
positive regulation of transcription by RNA polymerase II	Estrogen receptor	Homo sapiens (human)
negative regulation of transcription by RNA polymerase II	Estrogen receptor	Homo sapiens (human)
antral ovarian follicle growth	Estrogen receptor	Homo sapiens (human)
epithelial cell development	Estrogen receptor	Homo sapiens (human)
chromatin remodeling	Estrogen receptor	Homo sapiens (human)
regulation of DNA-templated transcription	Estrogen receptor	Homo sapiens (human)
signal transduction	Estrogen receptor	Homo sapiens (human)
phospholipase C-activating G protein-coupled receptor signaling pathway	Estrogen receptor	Homo sapiens (human)
positive regulation of cytosolic calcium ion concentration	Estrogen receptor	Homo sapiens (human)
androgen metabolic process	Estrogen receptor	Homo sapiens (human)
male gonad development	Estrogen receptor	Homo sapiens (human)
negative regulation of gene expression	Estrogen receptor	Homo sapiens (human)
positive regulation of phospholipase C activity	Estrogen receptor	Homo sapiens (human)
intracellular steroid hormone receptor signaling pathway	Estrogen receptor	Homo sapiens (human)
intracellular estrogen receptor signaling pathway	Estrogen receptor	Homo sapiens (human)
response to estradiol	Estrogen receptor	Homo sapiens (human)
regulation of toll-like receptor signaling pathway	Estrogen receptor	Homo sapiens (human)
negative regulation of smooth muscle cell apoptotic process	Estrogen receptor	Homo sapiens (human)
negative regulation of canonical NF-kappaB signal transduction	Estrogen receptor	Homo sapiens (human)
negative regulation of DNA-binding transcription factor activity	Estrogen receptor	Homo sapiens (human)
response to estrogen	Estrogen receptor	Homo sapiens (human)
positive regulation of DNA-templated transcription	Estrogen receptor	Homo sapiens (human)
positive regulation of transcription by RNA polymerase II	Estrogen receptor	Homo sapiens (human)
fibroblast proliferation	Estrogen receptor	Homo sapiens (human)
positive regulation of fibroblast proliferation	Estrogen receptor	Homo sapiens (human)
stem cell differentiation	Estrogen receptor	Homo sapiens (human)
regulation of inflammatory response	Estrogen receptor	Homo sapiens (human)
positive regulation of DNA-binding transcription factor activity	Estrogen receptor	Homo sapiens (human)
RNA polymerase II preinitiation complex assembly	Estrogen receptor	Homo sapiens (human)
uterus development	Estrogen receptor	Homo sapiens (human)
vagina development	Estrogen receptor	Homo sapiens (human)
prostate epithelial cord elongation	Estrogen receptor	Homo sapiens (human)
prostate epithelial cord arborization involved in prostate glandular acinus morphogenesis	Estrogen receptor	Homo sapiens (human)
regulation of branching involved in prostate gland morphogenesis	Estrogen receptor	Homo sapiens (human)
mammary gland branching involved in pregnancy	Estrogen receptor	Homo sapiens (human)
mammary gland alveolus development	Estrogen receptor	Homo sapiens (human)
epithelial cell proliferation involved in mammary gland duct elongation	Estrogen receptor	Homo sapiens (human)
protein localization to chromatin	Estrogen receptor	Homo sapiens (human)
cellular response to estradiol stimulus	Estrogen receptor	Homo sapiens (human)
negative regulation of miRNA transcription	Estrogen receptor	Homo sapiens (human)
regulation of epithelial cell apoptotic process	Estrogen receptor	Homo sapiens (human)
regulation of transcription by RNA polymerase II	Estrogen receptor	Homo sapiens (human)
cellular response to estrogen stimulus	Estrogen receptor	Homo sapiens (human)
negative regulation of transcription by RNA polymerase II	Glucocorticoid receptor	Homo sapiens (human)
regulation of gluconeogenesis	Glucocorticoid receptor	Homo sapiens (human)
chromatin organization	Glucocorticoid receptor	Homo sapiens (human)
regulation of DNA-templated transcription	Glucocorticoid receptor	Homo sapiens (human)
apoptotic process	Glucocorticoid receptor	Homo sapiens (human)
chromosome segregation	Glucocorticoid receptor	Homo sapiens (human)
signal transduction	Glucocorticoid receptor	Homo sapiens (human)
glucocorticoid metabolic process	Glucocorticoid receptor	Homo sapiens (human)
gene expression	Glucocorticoid receptor	Homo sapiens (human)
microglia differentiation	Glucocorticoid receptor	Homo sapiens (human)
adrenal gland development	Glucocorticoid receptor	Homo sapiens (human)
regulation of glucocorticoid biosynthetic process	Glucocorticoid receptor	Homo sapiens (human)
synaptic transmission, glutamatergic	Glucocorticoid receptor	Homo sapiens (human)
maternal behavior	Glucocorticoid receptor	Homo sapiens (human)
intracellular glucocorticoid receptor signaling pathway	Glucocorticoid receptor	Homo sapiens (human)
glucocorticoid mediated signaling pathway	Glucocorticoid receptor	Homo sapiens (human)
positive regulation of neuron apoptotic process	Glucocorticoid receptor	Homo sapiens (human)
negative regulation of DNA-templated transcription	Glucocorticoid receptor	Homo sapiens (human)
positive regulation of transcription by RNA polymerase II	Glucocorticoid receptor	Homo sapiens (human)
astrocyte differentiation	Glucocorticoid receptor	Homo sapiens (human)
cell division	Glucocorticoid receptor	Homo sapiens (human)
mammary gland duct morphogenesis	Glucocorticoid receptor	Homo sapiens (human)
motor behavior	Glucocorticoid receptor	Homo sapiens (human)
cellular response to steroid hormone stimulus	Glucocorticoid receptor	Homo sapiens (human)
cellular response to glucocorticoid stimulus	Glucocorticoid receptor	Homo sapiens (human)
cellular response to dexamethasone stimulus	Glucocorticoid receptor	Homo sapiens (human)
cellular response to transforming growth factor beta stimulus	Glucocorticoid receptor	Homo sapiens (human)
neuroinflammatory response	Glucocorticoid receptor	Homo sapiens (human)
positive regulation of miRNA transcription	Glucocorticoid receptor	Homo sapiens (human)
intracellular steroid hormone receptor signaling pathway	Glucocorticoid receptor	Homo sapiens (human)
regulation of transcription by RNA polymerase II	Glucocorticoid receptor	Homo sapiens (human)
ovulation from ovarian follicle	Progesterone receptor	Homo sapiens (human)
glandular epithelial cell maturation	Progesterone receptor	Homo sapiens (human)
regulation of DNA-templated transcription	Progesterone receptor	Homo sapiens (human)
signal transduction	Progesterone receptor	Homo sapiens (human)
G protein-coupled receptor signaling pathway	Progesterone receptor	Homo sapiens (human)
cell-cell signaling	Progesterone receptor	Homo sapiens (human)
positive regulation of gene expression	Progesterone receptor	Homo sapiens (human)
negative regulation of gene expression	Progesterone receptor	Homo sapiens (human)
paracrine signaling	Progesterone receptor	Homo sapiens (human)
negative regulation of phosphorylation	Progesterone receptor	Homo sapiens (human)
positive regulation of transcription by RNA polymerase II	Progesterone receptor	Homo sapiens (human)
lung alveolus development	Progesterone receptor	Homo sapiens (human)
regulation of epithelial cell proliferation	Progesterone receptor	Homo sapiens (human)
progesterone receptor signaling pathway	Progesterone receptor	Homo sapiens (human)
maintenance of protein location in nucleus	Progesterone receptor	Homo sapiens (human)
tertiary branching involved in mammary gland duct morphogenesis	Progesterone receptor	Homo sapiens (human)
regulation of transcription by RNA polymerase II	Progesterone receptor	Homo sapiens (human)
intracellular steroid hormone receptor signaling pathway	Progesterone receptor	Homo sapiens (human)
signal transduction	Mineralocorticoid receptor	Homo sapiens (human)
positive regulation of non-canonical NF-kappaB signal transduction	Mineralocorticoid receptor	Homo sapiens (human)
regulation of transcription by RNA polymerase II	Mineralocorticoid receptor	Homo sapiens (human)
intracellular steroid hormone receptor signaling pathway	Mineralocorticoid receptor	Homo sapiens (human)
negative regulation of transcription by RNA polymerase II	Androgen receptor	Homo sapiens (human)
MAPK cascade	Androgen receptor	Homo sapiens (human)
in utero embryonic development	Androgen receptor	Homo sapiens (human)
regulation of systemic arterial blood pressure	Androgen receptor	Homo sapiens (human)
epithelial cell morphogenesis	Androgen receptor	Homo sapiens (human)
transcription by RNA polymerase II	Androgen receptor	Homo sapiens (human)
signal transduction	Androgen receptor	Homo sapiens (human)
G protein-coupled receptor signaling pathway	Androgen receptor	Homo sapiens (human)
cell-cell signaling	Androgen receptor	Homo sapiens (human)
spermatogenesis	Androgen receptor	Homo sapiens (human)
single fertilization	Androgen receptor	Homo sapiens (human)
positive regulation of cell population proliferation	Androgen receptor	Homo sapiens (human)
negative regulation of cell population proliferation	Androgen receptor	Homo sapiens (human)
positive regulation of gene expression	Androgen receptor	Homo sapiens (human)
male somatic sex determination	Androgen receptor	Homo sapiens (human)
intracellular estrogen receptor signaling pathway	Androgen receptor	Homo sapiens (human)
androgen receptor signaling pathway	Androgen receptor	Homo sapiens (human)
intracellular receptor signaling pathway	Androgen receptor	Homo sapiens (human)
positive regulation of intracellular estrogen receptor signaling pathway	Androgen receptor	Homo sapiens (human)
Leydig cell differentiation	Androgen receptor	Homo sapiens (human)
multicellular organism growth	Androgen receptor	Homo sapiens (human)
positive regulation of phosphorylation	Androgen receptor	Homo sapiens (human)
positive regulation of MAPK cascade	Androgen receptor	Homo sapiens (human)
positive regulation of insulin-like growth factor receptor signaling pathway	Androgen receptor	Homo sapiens (human)
positive regulation of cell differentiation	Androgen receptor	Homo sapiens (human)
negative regulation of integrin biosynthetic process	Androgen receptor	Homo sapiens (human)
positive regulation of integrin biosynthetic process	Androgen receptor	Homo sapiens (human)
positive regulation of DNA-templated transcription	Androgen receptor	Homo sapiens (human)
positive regulation of transcription by RNA polymerase II	Androgen receptor	Homo sapiens (human)
positive regulation of transcription by RNA polymerase III	Androgen receptor	Homo sapiens (human)
insulin-like growth factor receptor signaling pathway	Androgen receptor	Homo sapiens (human)
regulation of developmental growth	Androgen receptor	Homo sapiens (human)
animal organ formation	Androgen receptor	Homo sapiens (human)
male genitalia morphogenesis	Androgen receptor	Homo sapiens (human)
epithelial cell proliferation	Androgen receptor	Homo sapiens (human)
negative regulation of epithelial cell proliferation	Androgen receptor	Homo sapiens (human)
positive regulation of NF-kappaB transcription factor activity	Androgen receptor	Homo sapiens (human)
activation of prostate induction by androgen receptor signaling pathway	Androgen receptor	Homo sapiens (human)
morphogenesis of an epithelial fold	Androgen receptor	Homo sapiens (human)
lateral sprouting involved in mammary gland duct morphogenesis	Androgen receptor	Homo sapiens (human)
prostate gland growth	Androgen receptor	Homo sapiens (human)
prostate gland epithelium morphogenesis	Androgen receptor	Homo sapiens (human)
epithelial cell differentiation involved in prostate gland development	Androgen receptor	Homo sapiens (human)
tertiary branching involved in mammary gland duct morphogenesis	Androgen receptor	Homo sapiens (human)
mammary gland alveolus development	Androgen receptor	Homo sapiens (human)
positive regulation of epithelial cell proliferation involved in prostate gland development	Androgen receptor	Homo sapiens (human)
cellular response to steroid hormone stimulus	Androgen receptor	Homo sapiens (human)
cellular response to estrogen stimulus	Androgen receptor	Homo sapiens (human)
cellular response to testosterone stimulus	Androgen receptor	Homo sapiens (human)
seminiferous tubule development	Androgen receptor	Homo sapiens (human)
non-membrane-bounded organelle assembly	Androgen receptor	Homo sapiens (human)
positive regulation of miRNA transcription	Androgen receptor	Homo sapiens (human)
regulation of protein localization to plasma membrane	Androgen receptor	Homo sapiens (human)
negative regulation of extrinsic apoptotic signaling pathway	Androgen receptor	Homo sapiens (human)
male gonad development	Androgen receptor	Homo sapiens (human)
intracellular steroid hormone receptor signaling pathway	Androgen receptor	Homo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Process	via Protein(s)	Taxonomy
RNA polymerase II cis-regulatory region sequence-specific DNA binding	Estrogen receptor	Homo sapiens (human)
DNA-binding transcription factor activity, RNA polymerase II-specific	Estrogen receptor	Homo sapiens (human)
TFIIB-class transcription factor binding	Estrogen receptor	Homo sapiens (human)
transcription coregulator binding	Estrogen receptor	Homo sapiens (human)
transcription corepressor binding	Estrogen receptor	Homo sapiens (human)
transcription coactivator binding	Estrogen receptor	Homo sapiens (human)
DNA-binding transcription activator activity, RNA polymerase II-specific	Estrogen receptor	Homo sapiens (human)
chromatin binding	Estrogen receptor	Homo sapiens (human)
DNA-binding transcription factor activity	Estrogen receptor	Homo sapiens (human)
nuclear receptor activity	Estrogen receptor	Homo sapiens (human)
steroid binding	Estrogen receptor	Homo sapiens (human)
protein binding	Estrogen receptor	Homo sapiens (human)
calmodulin binding	Estrogen receptor	Homo sapiens (human)
beta-catenin binding	Estrogen receptor	Homo sapiens (human)
zinc ion binding	Estrogen receptor	Homo sapiens (human)
TBP-class protein binding	Estrogen receptor	Homo sapiens (human)
enzyme binding	Estrogen receptor	Homo sapiens (human)
protein kinase binding	Estrogen receptor	Homo sapiens (human)
nitric-oxide synthase regulator activity	Estrogen receptor	Homo sapiens (human)
nuclear estrogen receptor activity	Estrogen receptor	Homo sapiens (human)
nuclear estrogen receptor binding	Estrogen receptor	Homo sapiens (human)
estrogen response element binding	Estrogen receptor	Homo sapiens (human)
identical protein binding	Estrogen receptor	Homo sapiens (human)
ATPase binding	Estrogen receptor	Homo sapiens (human)
14-3-3 protein binding	Estrogen receptor	Homo sapiens (human)
sequence-specific double-stranded DNA binding	Estrogen receptor	Homo sapiens (human)
RNA polymerase II transcription regulatory region sequence-specific DNA binding	Glucocorticoid receptor	Homo sapiens (human)
RNA polymerase II cis-regulatory region sequence-specific DNA binding	Glucocorticoid receptor	Homo sapiens (human)
DNA-binding transcription factor activity, RNA polymerase II-specific	Glucocorticoid receptor	Homo sapiens (human)
core promoter sequence-specific DNA binding	Glucocorticoid receptor	Homo sapiens (human)
DNA-binding transcription repressor activity, RNA polymerase II-specific	Glucocorticoid receptor	Homo sapiens (human)
DNA-binding transcription activator activity, RNA polymerase II-specific	Glucocorticoid receptor	Homo sapiens (human)
DNA-binding transcription factor activity	Glucocorticoid receptor	Homo sapiens (human)
RNA binding	Glucocorticoid receptor	Homo sapiens (human)
nuclear receptor activity	Glucocorticoid receptor	Homo sapiens (human)
nuclear glucocorticoid receptor activity	Glucocorticoid receptor	Homo sapiens (human)
steroid binding	Glucocorticoid receptor	Homo sapiens (human)
protein binding	Glucocorticoid receptor	Homo sapiens (human)
zinc ion binding	Glucocorticoid receptor	Homo sapiens (human)
TBP-class protein binding	Glucocorticoid receptor	Homo sapiens (human)
protein kinase binding	Glucocorticoid receptor	Homo sapiens (human)
identical protein binding	Glucocorticoid receptor	Homo sapiens (human)
Hsp90 protein binding	Glucocorticoid receptor	Homo sapiens (human)
steroid hormone binding	Glucocorticoid receptor	Homo sapiens (human)
sequence-specific double-stranded DNA binding	Glucocorticoid receptor	Homo sapiens (human)
estrogen response element binding	Glucocorticoid receptor	Homo sapiens (human)
RNA polymerase II cis-regulatory region sequence-specific DNA binding	Progesterone receptor	Homo sapiens (human)
DNA-binding transcription factor activity, RNA polymerase II-specific	Progesterone receptor	Homo sapiens (human)
transcription coactivator binding	Progesterone receptor	Homo sapiens (human)
DNA-binding transcription activator activity, RNA polymerase II-specific	Progesterone receptor	Homo sapiens (human)
DNA binding	Progesterone receptor	Homo sapiens (human)
nuclear steroid receptor activity	Progesterone receptor	Homo sapiens (human)
G protein-coupled receptor activity	Progesterone receptor	Homo sapiens (human)
steroid binding	Progesterone receptor	Homo sapiens (human)
protein binding	Progesterone receptor	Homo sapiens (human)
zinc ion binding	Progesterone receptor	Homo sapiens (human)
enzyme binding	Progesterone receptor	Homo sapiens (human)
identical protein binding	Progesterone receptor	Homo sapiens (human)
ATPase binding	Progesterone receptor	Homo sapiens (human)
estrogen response element binding	Progesterone receptor	Homo sapiens (human)
nuclear receptor activity	Progesterone receptor	Homo sapiens (human)
DNA-binding transcription factor activity, RNA polymerase II-specific	Mineralocorticoid receptor	Homo sapiens (human)
DNA-binding transcription factor activity	Mineralocorticoid receptor	Homo sapiens (human)
nuclear steroid receptor activity	Mineralocorticoid receptor	Homo sapiens (human)
steroid binding	Mineralocorticoid receptor	Homo sapiens (human)
protein binding	Mineralocorticoid receptor	Homo sapiens (human)
zinc ion binding	Mineralocorticoid receptor	Homo sapiens (human)
TBP-class protein binding	Mineralocorticoid receptor	Homo sapiens (human)
sequence-specific double-stranded DNA binding	Mineralocorticoid receptor	Homo sapiens (human)
nuclear receptor activity	Mineralocorticoid receptor	Homo sapiens (human)
estrogen response element binding	Mineralocorticoid receptor	Homo sapiens (human)
transcription cis-regulatory region binding	Androgen receptor	Homo sapiens (human)
RNA polymerase II cis-regulatory region sequence-specific DNA binding	Androgen receptor	Homo sapiens (human)
DNA-binding transcription factor activity, RNA polymerase II-specific	Androgen receptor	Homo sapiens (human)
RNA polymerase II general transcription initiation factor binding	Androgen receptor	Homo sapiens (human)
transcription coactivator binding	Androgen receptor	Homo sapiens (human)
DNA-binding transcription activator activity, RNA polymerase II-specific	Androgen receptor	Homo sapiens (human)
chromatin binding	Androgen receptor	Homo sapiens (human)
DNA-binding transcription factor activity	Androgen receptor	Homo sapiens (human)
nuclear receptor activity	Androgen receptor	Homo sapiens (human)
G protein-coupled receptor activity	Androgen receptor	Homo sapiens (human)
signaling receptor binding	Androgen receptor	Homo sapiens (human)
steroid binding	Androgen receptor	Homo sapiens (human)
androgen binding	Androgen receptor	Homo sapiens (human)
protein binding	Androgen receptor	Homo sapiens (human)
beta-catenin binding	Androgen receptor	Homo sapiens (human)
zinc ion binding	Androgen receptor	Homo sapiens (human)
enzyme binding	Androgen receptor	Homo sapiens (human)
ATPase binding	Androgen receptor	Homo sapiens (human)
molecular adaptor activity	Androgen receptor	Homo sapiens (human)
RNA polymerase II-specific DNA-binding transcription factor binding	Androgen receptor	Homo sapiens (human)
POU domain binding	Androgen receptor	Homo sapiens (human)
molecular condensate scaffold activity	Androgen receptor	Homo sapiens (human)
estrogen response element binding	Androgen receptor	Homo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Process	via Protein(s)	Taxonomy
nucleus	Estrogen receptor	Homo sapiens (human)
nucleoplasm	Estrogen receptor	Homo sapiens (human)
transcription regulator complex	Estrogen receptor	Homo sapiens (human)
cytoplasm	Estrogen receptor	Homo sapiens (human)
Golgi apparatus	Estrogen receptor	Homo sapiens (human)
cytosol	Estrogen receptor	Homo sapiens (human)
plasma membrane	Estrogen receptor	Homo sapiens (human)
membrane	Estrogen receptor	Homo sapiens (human)
chromatin	Estrogen receptor	Homo sapiens (human)
euchromatin	Estrogen receptor	Homo sapiens (human)
protein-containing complex	Estrogen receptor	Homo sapiens (human)
nucleus	Estrogen receptor	Homo sapiens (human)
nucleus	Glucocorticoid receptor	Homo sapiens (human)
nucleus	Glucocorticoid receptor	Homo sapiens (human)
nucleoplasm	Glucocorticoid receptor	Homo sapiens (human)
cytoplasm	Glucocorticoid receptor	Homo sapiens (human)
mitochondrial matrix	Glucocorticoid receptor	Homo sapiens (human)
centrosome	Glucocorticoid receptor	Homo sapiens (human)
spindle	Glucocorticoid receptor	Homo sapiens (human)
cytosol	Glucocorticoid receptor	Homo sapiens (human)
membrane	Glucocorticoid receptor	Homo sapiens (human)
nuclear speck	Glucocorticoid receptor	Homo sapiens (human)
synapse	Glucocorticoid receptor	Homo sapiens (human)
chromatin	Glucocorticoid receptor	Homo sapiens (human)
protein-containing complex	Glucocorticoid receptor	Homo sapiens (human)
plasma membrane	Progesterone receptor	Homo sapiens (human)
nucleoplasm	Progesterone receptor	Homo sapiens (human)
mitochondrial outer membrane	Progesterone receptor	Homo sapiens (human)
cytosol	Progesterone receptor	Homo sapiens (human)
chromatin	Progesterone receptor	Homo sapiens (human)
nucleus	Progesterone receptor	Homo sapiens (human)
nucleoplasm	Mineralocorticoid receptor	Homo sapiens (human)
endoplasmic reticulum membrane	Mineralocorticoid receptor	Homo sapiens (human)
cytosol	Mineralocorticoid receptor	Homo sapiens (human)
chromatin	Mineralocorticoid receptor	Homo sapiens (human)
receptor complex	Mineralocorticoid receptor	Homo sapiens (human)
nucleus	Mineralocorticoid receptor	Homo sapiens (human)
plasma membrane	Androgen receptor	Homo sapiens (human)
nucleus	Androgen receptor	Homo sapiens (human)
nucleoplasm	Androgen receptor	Homo sapiens (human)
cytoplasm	Androgen receptor	Homo sapiens (human)
cytosol	Androgen receptor	Homo sapiens (human)
nuclear speck	Androgen receptor	Homo sapiens (human)
chromatin	Androgen receptor	Homo sapiens (human)
protein-containing complex	Androgen receptor	Homo sapiens (human)
nucleus	Androgen receptor	Homo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Bioassays (25)

Assay ID	Title	Year	Journal	Article
AID323987	Agonist activity at human PRB expressed in CHO cells	2008	Bioorganic & medicinal chemistry, Mar-15, Volume: 16, Issue:6	11-(pyridinylphenyl)steroids--a new class of mixed-profile progesterone agonists/antagonists.
AID323989	Antagonist activity at human PRB expressed in CHO cells assessed as inhibition of Org 2058 induced-transactivation	2008	Bioorganic & medicinal chemistry, Mar-15, Volume: 16, Issue:6	11-(pyridinylphenyl)steroids--a new class of mixed-profile progesterone agonists/antagonists.
AID719377	Agonist activity at estrogen receptor by cellular reporter gene assay	2012	Bioorganic & medicinal chemistry letters, Dec-01, Volume: 22, Issue:23	Novel progesterone receptor modulators: 4-aryl-phenylsulfonamides.
AID326404	Antagonist activity at human GR ligand binding domain expressed in african green monkey COS7 cells in presence of Dexamethasone by Gal4 hybrid assay	2008	Journal of medicinal chemistry, Mar-27, Volume: 51, Issue:6	Design, synthesis, and SAR of new pyrrole-oxindole progesterone receptor modulators leading to 5-(7-fluoro-3,3-dimethyl-2-oxo-2,3-dihydro-1H-indol-5-yl)-1-methyl-1H-pyrrole-2-carbonitrile (WAY-255348).
AID719375	Antagonist activity at progesterone receptor by cellular reporter gene assay	2012	Bioorganic & medicinal chemistry letters, Dec-01, Volume: 22, Issue:23	Novel progesterone receptor modulators: 4-aryl-phenylsulfonamides.
AID326408	Antagonist activity at human ER ligand binding domain expressed in african green monkey COS7 cells in presence of 17-beta-estradiol by Gal4 hybrid assay	2008	Journal of medicinal chemistry, Mar-27, Volume: 51, Issue:6	Design, synthesis, and SAR of new pyrrole-oxindole progesterone receptor modulators leading to 5-(7-fluoro-3,3-dimethyl-2-oxo-2,3-dihydro-1H-indol-5-yl)-1-methyl-1H-pyrrole-2-carbonitrile (WAY-255348).
AID326401	Agonist activity at human AR ligand binding domain expressed in african green monkey COS7 cells by Gal4 hybrid assay	2008	Journal of medicinal chemistry, Mar-27, Volume: 51, Issue:6	Design, synthesis, and SAR of new pyrrole-oxindole progesterone receptor modulators leading to 5-(7-fluoro-3,3-dimethyl-2-oxo-2,3-dihydro-1H-indol-5-yl)-1-methyl-1H-pyrrole-2-carbonitrile (WAY-255348).
AID719371	Antagonist activity at estrogen receptor by cellular reporter gene assay	2012	Bioorganic & medicinal chemistry letters, Dec-01, Volume: 22, Issue:23	Novel progesterone receptor modulators: 4-aryl-phenylsulfonamides.
AID719521	Agonist activity at progesterone receptor by cellular reporter gene assay	2012	Bioorganic & medicinal chemistry letters, Dec-01, Volume: 22, Issue:23	Novel progesterone receptor modulators: 4-aryl-phenylsulfonamides.
AID326407	Agonist activity at human ER ligand binding domain expressed in african green monkey COS7 cells by Gal4 hybrid assay	2008	Journal of medicinal chemistry, Mar-27, Volume: 51, Issue:6	Design, synthesis, and SAR of new pyrrole-oxindole progesterone receptor modulators leading to 5-(7-fluoro-3,3-dimethyl-2-oxo-2,3-dihydro-1H-indol-5-yl)-1-methyl-1H-pyrrole-2-carbonitrile (WAY-255348).
AID570060	Antagonist activity at progesterone receptor in orally dosed ovariectomized Sprague-Dawley rat assessed as reversal of R5020-induced down-regulation of estradiol-induced increase in complement 3 mRNA expression by C3 rat uterine assay	2011	ACS medicinal chemistry letters, Feb-10, Volume: 2, Issue:2	Novel 3-aryl indoles as progesterone receptor antagonists for uterine fibroids.
AID326405	Agonist activity at human MR ligand binding domain receptor expressed in african green monkey COS7 cells by Gal4 hybrid assay	2008	Journal of medicinal chemistry, Mar-27, Volume: 51, Issue:6	Design, synthesis, and SAR of new pyrrole-oxindole progesterone receptor modulators leading to 5-(7-fluoro-3,3-dimethyl-2-oxo-2,3-dihydro-1H-indol-5-yl)-1-methyl-1H-pyrrole-2-carbonitrile (WAY-255348).
AID719373	Antagonist activity at glucocorticoid receptor by cellular reporter gene assay	2012	Bioorganic & medicinal chemistry letters, Dec-01, Volume: 22, Issue:23	Novel progesterone receptor modulators: 4-aryl-phenylsulfonamides.
AID719519	Agonist activity at glucocorticoid receptor by cellular reporter gene assay	2012	Bioorganic & medicinal chemistry letters, Dec-01, Volume: 22, Issue:23	Novel progesterone receptor modulators: 4-aryl-phenylsulfonamides.
AID326403	Agonist activity at human GR ligand binding domain expressed in african green monkey COS7 cells by Gal4 hybrid assay	2008	Journal of medicinal chemistry, Mar-27, Volume: 51, Issue:6	Design, synthesis, and SAR of new pyrrole-oxindole progesterone receptor modulators leading to 5-(7-fluoro-3,3-dimethyl-2-oxo-2,3-dihydro-1H-indol-5-yl)-1-methyl-1H-pyrrole-2-carbonitrile (WAY-255348).
AID719374	Antagonist activity at androgen receptor by cellular reporter gene assay	2012	Bioorganic & medicinal chemistry letters, Dec-01, Volume: 22, Issue:23	Novel progesterone receptor modulators: 4-aryl-phenylsulfonamides.
AID326406	Antagonist activity at human MR ligand binding domain expressed in african green monkey COS7 cells in presence of aldosterone by Gal4 hybrid assay	2008	Journal of medicinal chemistry, Mar-27, Volume: 51, Issue:6	Design, synthesis, and SAR of new pyrrole-oxindole progesterone receptor modulators leading to 5-(7-fluoro-3,3-dimethyl-2-oxo-2,3-dihydro-1H-indol-5-yl)-1-methyl-1H-pyrrole-2-carbonitrile (WAY-255348).
AID719378	Agonist activity at mineralocorticoid receptor by cellular reporter gene assay	2012	Bioorganic & medicinal chemistry letters, Dec-01, Volume: 22, Issue:23	Novel progesterone receptor modulators: 4-aryl-phenylsulfonamides.
AID323990	Antagonist activity at human PRB expressed in CHO cells assessed as inhibition of Org 2058 induced-transactivation relative to Org 31710	2008	Bioorganic & medicinal chemistry, Mar-15, Volume: 16, Issue:6	11-(pyridinylphenyl)steroids--a new class of mixed-profile progesterone agonists/antagonists.
AID570063	Agonist activity at progesterone receptor in estrogen-primed immature New Zealand White rabbit assessed as stimulation of progesterone-induced endometrial transformation at 30 mg/kg, sc by McPhail assay	2011	ACS medicinal chemistry letters, Feb-10, Volume: 2, Issue:2	Novel 3-aryl indoles as progesterone receptor antagonists for uterine fibroids.
AID719520	Agonist activity at androgen receptor by cellular reporter gene assay	2012	Bioorganic & medicinal chemistry letters, Dec-01, Volume: 22, Issue:23	Novel progesterone receptor modulators: 4-aryl-phenylsulfonamides.
AID719529	Antagonist activity against progesterone receptor in human T47D cells by alkaline phosphatase assay	2012	Bioorganic & medicinal chemistry letters, Dec-01, Volume: 22, Issue:23	Novel progesterone receptor modulators: 4-aryl-phenylsulfonamides.
AID570061	Antagonist activity at progesterone receptor in estrogen-primed immature New Zealand White rabbit assessed as inhibition of progesterone-induced endometrial transformation at 1 mg/kg, sc by McPhail assay	2011	ACS medicinal chemistry letters, Feb-10, Volume: 2, Issue:2	Novel 3-aryl indoles as progesterone receptor antagonists for uterine fibroids.
AID719372	Antagonist activity at mineralocorticoid receptor by cellular reporter gene assay	2012	Bioorganic & medicinal chemistry letters, Dec-01, Volume: 22, Issue:23	Novel progesterone receptor modulators: 4-aryl-phenylsulfonamides.
AID326402	Antagonist activity at human AR ligand binding domain expressed in african green monkey COS7 cells in presence of 5-alpha-dihydrotestosterone by Gal4 hybrid assay	2008	Journal of medicinal chemistry, Mar-27, Volume: 51, Issue:6	Design, synthesis, and SAR of new pyrrole-oxindole progesterone receptor modulators leading to 5-(7-fluoro-3,3-dimethyl-2-oxo-2,3-dihydro-1H-indol-5-yl)-1-methyl-1H-pyrrole-2-carbonitrile (WAY-255348).
[information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023]

Timeframe	Studies, This Drug (%)	All Drugs %
pre-1990	0 (0.00)	18.7374
1990's	0 (0.00)	18.2507
2000's	25 (56.82)	29.6817
2010's	18 (40.91)	24.3611
2020's	1 (2.27)	2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Publication Type	This drug (%)	All Drugs (%)
Trials	8 (16.67%)	5.53%
Reviews	18 (37.50%)	6.00%
Case Studies	0 (0.00%)	4.05%
Observational	0 (0.00%)	0.25%
Other	22 (45.83%)	84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Substance	Relationship Strength	Studies	Trials	Classes	Roles
tranexamic acid Tranexamic Acid: Antifibrinolytic hemostatic used in severe hemorrhage.	4.14	1	0	amino acid
medroxyprogesterone acetate [no description available]	3.23	1	0	20-oxo steroid; 3-oxo-Delta(4) steroid; acetate ester; corticosteroid; steroid ester	adjuvant; androgen; antineoplastic agent; antioxidant; female contraceptive drug; inhibitor; progestin; synthetic oral contraceptive
dehydroepiandrosterone sulfate Dehydroepiandrosterone Sulfate: The circulating form of a major C19 steroid produced primarily by the ADRENAL CORTEX. DHEA sulfate serves as a precursor for TESTOSTERONE; ANDROSTENEDIONE; ESTRADIOL; and ESTRONE.. dehydroepiandrosterone sulfate : A steroid sulfate that is the 3-sulfooxy derivative of dehydroepiandrosterone.	3.41	1	1	17-oxo steroid; steroid sulfate	EC 2.7.1.33 (pantothenate kinase) inhibitor; human metabolite; mouse metabolite
levonorgestrel Levonorgestrel: A synthetic progestational hormone with actions similar to those of PROGESTERONE and about twice as potent as its racemic or (+-)-isomer (NORGESTREL). It is used for contraception, control of menstrual disorders, and treatment of endometriosis.	6.13	4	0	17beta-hydroxy steroid; 3-oxo-Delta(4) steroid; terminal acetylenic compound	contraceptive drug; female contraceptive drug; progestin; synthetic oral contraceptive
gestrinone Gestrinone: A non-estrogenic contraceptive which is a weak progestin with strong anti-progesterone properties. It is effective if used once a week orally or can also be used in intravaginal devices.	5.07	2	0	oxo steroid
danazol Danazol: A synthetic steroid with antigonadotropic and anti-estrogenic activities that acts as an anterior pituitary suppressant by inhibiting the pituitary output of gonadotropins. It possesses some androgenic properties. Danazol has been used in the treatment of endometriosis and some benign breast disorders.	5.07	2	0	17beta-hydroxy steroid; terminal acetylenic compound	anti-estrogen; estrogen antagonist; geroprotector
cabergoline Cabergoline: An ergoline derivative and dopamine D2-agonist that inhibits PROLACTIN secretion. It is used in the management of HYPERPROLACTINEMIA, and to suppress lactation following childbirth for medical reasons. Cabergoline is also used in the management of PARKINSON DISEASE.. cabergoline : An N-acylurea that is (8R)-ergoline-8-carboxamide in which the hydrogen attached to the piperidine nitrogen (position 6) is substituted by an allyl group and the hydrogens attached to the carboxamide nitrogen are substituted by a 3-(dimethylamino)propyl group and an N-ethylcarbamoyl group. A dopamine D2 receptor agonist, cabergoline is used in the management of Parkinson's disease and of disorders associated with hyperprolactinaemia.	4.14	1	0	N-acylurea	antineoplastic agent; antiparkinson drug; dopamine agonist
mifepristone Mifepristone: A progestational and glucocorticoid hormone antagonist. Its inhibition of progesterone induces bleeding during the luteal phase and in early pregnancy by releasing endogenous prostaglandins from the endometrium or decidua. As a glucocorticoid receptor antagonist, the drug has been used to treat hypercortisolism in patients with nonpituitary CUSHING SYNDROME.	8.02	15	0	3-oxo-Delta(4) steroid; acetylenic compound; tertiary amino compound	abortifacient; contraceptive drug; hormone antagonist; synthetic oral contraceptive
fulvestrant Fulvestrant: An estradiol derivative and estrogen receptor antagonist that is used for the treatment of estrogen receptor-positive, locally advanced or metastatic breast cancer.. fulvestrant : A 3-hydroxy steroid that is 17beta-estradiol in which the 7alpha hydrogen has been replaced by a nonyl group in which one of the hydrogens of the terminal methyl has been replaced by a (4,4,5,5,5-pentafluoropentyl)sulfinyl group. An estrogen receptor antagonist, it is used in the treatment of breast cancer.	3.23	1	0	17beta-hydroxy steroid; 3-hydroxy steroid; organofluorine compound; sulfoxide	antineoplastic agent; estrogen antagonist; estrogen receptor antagonist
ulipristal acetate RTI 3021-012: progesterone receptor antagonist. ulipristal acetate : A 20-oxo steroid obtained by acetylation of the 17-hydroxy group of (11beta,17alpha)-17-acetyl-11-[4-(dimethylamino)phenyl]-3-oxoestra-4,9-dien-17-ol (ulipristal). A selective progesterone receptor modulator, which is employed as an emergency contraceptive.	7.19	9	0	20-oxo steroid; 3-oxo-Delta(4) steroid; acetate ester; steroid ester; tertiary amino compound	contraceptive drug; progesterone receptor modulator; progestin
leuprolide Leuprolide: A potent synthetic long-acting agonist of GONADOTROPIN-RELEASING HORMONE that regulates the synthesis and release of pituitary gonadotropins, LUTEINIZING HORMONE and FOLLICLE STIMULATING HORMONE.. leuprolide : An oligopeptide comprising pyroglutamyl, histidyl, tryptophyl, seryl, tyrosyl, D-leucyl, leucyl, arginyl, and N-ethylprolinamide residues joined in sequence. It is a synthetic nonapeptide analogue of gonadotropin-releasing hormone, and is used as a subcutaneous hydrogel implant (particularly as the acetate salt) for the treatment of prostate cancer and for the suppression of gonadal sex hormone production in children with central precocious puberty.	4.16	2	0	oligopeptide	anti-estrogen; antineoplastic agent; gonadotropin releasing hormone agonist
curcumin Curcumin: A yellow-orange dye obtained from tumeric, the powdered root of CURCUMA longa. It is used in the preparation of curcuma paper and the detection of boron. Curcumin appears to possess a spectrum of pharmacological properties, due primarily to its inhibitory effects on metabolic enzymes.. curcumin : A beta-diketone that is methane in which two of the hydrogens are substituted by feruloyl groups. A natural dyestuff found in the root of Curcuma longa.	3.23	1	0	aromatic ether; beta-diketone; diarylheptanoid; enone; polyphenol	anti-inflammatory agent; antifungal agent; antineoplastic agent; biological pigment; contraceptive drug; dye; EC 1.1.1.205 (IMP dehydrogenase) inhibitor; EC 1.1.1.21 (aldehyde reductase) inhibitor; EC 1.1.1.25 (shikimate dehydrogenase) inhibitor; EC 1.6.5.2 [NAD(P)H dehydrogenase (quinone)] inhibitor; EC 1.8.1.9 (thioredoxin reductase) inhibitor; EC 2.7.10.2 (non-specific protein-tyrosine kinase) inhibitor; EC 3.5.1.98 (histone deacetylase) inhibitor; flavouring agent; food colouring; geroprotector; hepatoprotective agent; immunomodulator; iron chelator; ligand; lipoxygenase inhibitor; metabolite; neuroprotective agent; nutraceutical; radical scavenger
tanaproget tanaproget: structure in first source	3.54	2	0
cholecalciferol Cholecalciferol: Derivative of 7-dehydroxycholesterol formed by ULTRAVIOLET RAYS breaking of the C9-C10 bond. It differs from ERGOCALCIFEROL in having a single bond between C22 and C23 and lacking a methyl group at C24.. calciol : A hydroxy seco-steroid that is (5Z,7E)-9,10-secocholesta-5,7,10(19)-triene in which the pro-S hydrogen at position 3 has been replaced by a hydroxy group. It is the inactive form of vitamin D3, being hydroxylated in the liver to calcidiol (25-hydroxyvitamin D3), which is then further hydroxylated in the kidney to give calcitriol (1,25-dihydroxyvitamin D3), the active hormone.	4.14	1	0	D3 vitamins; hydroxy seco-steroid; seco-cholestane; secondary alcohol; steroid hormone	geroprotector; human metabolite
onapristone onapristone: induces vaginal bleeding and luteal regression in monkeys; structure given in first source; progesterone antagonist	3.55	2	0
pregnanediol [no description available]	3.43	1	1
ergoline Ergolines: A series of structurally-related alkaloids that contain the ergoline backbone structure.. ergoline : An indole alkaloid whose structural skeleton is found in many naturally occurring and synthetic ergolines which are known to bind to neurotransmitter receptors, such as dopamine, noradrenaline and serotonin receptors and function as unselective agonists or antagonists at these receptors.	4.14	1	0	diamine; ergoline alkaloid; indole alkaloid fundamental parent; indole alkaloid; organic heterotetracyclic compound
telapristone acetate telapristone acetate: structure in first source	5.21	4	0	steroid ester
bio 1211 BIO 1211: integrin alpha4beta1 inhibitor; structure in first source	3.41	1	1
ulipristal ulipristal: a progestins antagonist	4.92	4	0	20-oxo steroid
vilaprisan vilaprisan: a progesterone receptor modulator; structure in first source	3.27	1	0
epidermal growth factor Epidermal Growth Factor: A 6-kDa polypeptide growth factor initially discovered in mouse submaxillary glands. Human epidermal growth factor was originally isolated from urine based on its ability to inhibit gastric secretion and called urogastrone. Epidermal growth factor exerts a wide variety of biological effects including the promotion of proliferation and differentiation of mesenchymal and EPITHELIAL CELLS. It is synthesized as a transmembrane protein which can be cleaved to release a soluble active form.	2.44	2	0
transforming growth factor beta Transforming Growth Factor beta: A factor synthesized in a wide variety of tissues. It acts synergistically with TGF-alpha in inducing phenotypic transformation and can also act as a negative autocrine growth factor. TGF-beta has a potential role in embryonal development, cellular differentiation, hormone secretion, and immune function. TGF-beta is found mostly as homodimer forms of separate gene products TGF-beta1, TGF-beta2 or TGF-beta3. Heterodimers composed of TGF-beta1 and 2 (TGF-beta1.2) or of TGF-beta2 and 3 (TGF-beta2.3) have been isolated. The TGF-beta proteins are synthesized as precursor proteins.	2.03	1	0
contraceptives, postcoital Contraceptives, Postcoital: Contraceptive substances to be used after COITUS. These agents include high doses of estrogenic drugs; progesterone-receptor blockers; ANTIMETABOLITES; ALKALOIDS, and PROSTAGLANDINS.	3.19	1	0

Condition	Indicated	Relationship Strength	Studies	Trials
Fibroid [description not available]	0	15.31	39	18
Cancer of the Uterus [description not available]	0	14.99	35	17
Leiomyoma A benign tumor derived from smooth muscle tissue, also known as a fibroid tumor. They rarely occur outside of the UTERUS and the GASTROINTESTINAL TRACT but can occur in the SKIN and SUBCUTANEOUS TISSUE, probably arising from the smooth muscle of small blood vessels in these tissues.	1	20.01	78	36
Uterine Neoplasms Tumors or cancer of the UTERUS.	0	14.99	35	17
B16 Melanoma [description not available]	0	2.25	1	0
Postpartum Amenorrhea [description not available]	0	3.06	1	0
Pelvic Pain Pain in the pelvic region of genital and non-genital origin.	0	3.06	1	0
Amenorrhea Absence of menstruation.	0	3.06	1	0
Menstruation, Painful [description not available]	0	3.06	1	0
Endometrioma An enlarged area of ENDOMETRIOSIS that resembles a tumor. It is usually found in the OVARY. When it is filled with old blood, it is known as a chocolate cyst.	0	5.29	5	0
Dysmenorrhea Painful menstruation.	0	3.06	1	0
Dyspareunia Recurrent genital pain occurring during, before, or after SEXUAL INTERCOURSE in either the male or the female.	0	3.06	1	0
Endometriosis A condition in which functional endometrial tissue is present outside the UTERUS. It is often confined to the PELVIS involving the OVARY, the ligaments, cul-de-sac, and the uterovesical peritoneum.	1	7.29	5	0
Heavy Menstrual Bleeding [description not available]	0	10.76	13	13
Menorrhagia Excessive uterine bleeding during MENSTRUATION.	1	12.76	13	13
Pregnancy The status during which female mammals carry their developing young (EMBRYOS or FETUSES) in utero before birth, beginning from FERTILIZATION to BIRTH.	0	2.48	2	0
Adenomyosis The extension of endometrial tissue (ENDOMETRIUM) into the MYOMETRIUM. It usually occurs in women in their reproductive years and may result in a diffusely enlarged uterus with ectopic and benign endometrial glands and stroma.	0	3.01	1	0
Hemorrhage, Uterine [description not available]	0	7.19	4	2
Uterine Hemorrhage Bleeding from blood vessels in the UTERUS, sometimes manifested as vaginal bleeding.	0	7.19	4	2
Breast Cancer [description not available]	0	2.44	2	0
Breast Neoplasms Tumors or cancer of the human BREAST.	0	2.44	2	0
Hyperplasia An increase in the number of cells in a tissue or organ without tumor formation. It differs from HYPERTROPHY, which is an increase in bulk without an increase in the number of cells.	0	2.99	1	0

asoprisnil

Description

Cross-References

Synonyms (35)

Research Excerpts

Overview

Treatment

Toxicity

Dosage Studied

Protein Targets (5)

Inhibition Measurements

Activation Measurements

Biological Processes (121)

Molecular Functions (44)

Ceullar Components (19)

Bioassays (25)

Research

Studies (44)

Market Indicators

Research Demand Index: 34.03

Study Types

asoprisnil

Description

Cross-References

Synonyms (35)

Research Excerpts

Overview

Treatment

Toxicity

Dosage Studied

Protein Targets (5)

Inhibition Measurements

Activation Measurements

Biological Processes (121)

Molecular Functions (44)

Ceullar Components (19)

Bioassays (25)

Research

Studies (44)

Market Indicators

Research Demand Index: 34.03

Study Types

Related Drugs (24)

Related Conditions (22)